POM-V Prescription Required Companion Animal

Maropicord 10 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Maropitant

Form

Injection

Species

Cats Dogs

Manufacturer

Accord Healthcare B.V

VMD MA No.

42153/5003

What it's used for

Cats • motion sickness. •

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Maropitant

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Maropicord 10 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Cats
•
motion sickness.
•

Veterinary medicinal product should be injected subcutaneously or intravenously,
once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5
consecutive days. Intravenous administration of Veterinary medicinal product should
be given as a single bolus without mixing the veterinary medicinal product with any
other fluids.
In dogs, veterinary medicinal product can be used to treat or prevent vomiting as
solution for injection administered once daily. Veterinary medicinal product may be
administered for up to five days.
To prevent vomiting, veterinary medicinal product should be administered more than
1 hour in advance. The effect duration is approximately 24 h and therefore treatment
can be given the night before administration of an agent that may cause emesis e.g.
chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the body
after once daily repeated administration, lower doses than recommended might be
sufficient in some individuals and when repeating the dose.

AN: 04158 & 04159/2024
None.

Dogs and cats:
Very common
(>1 animal / 10 animals treated):
Injection site pain
1,2
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Anaphylactic-type reaction (e.g. allergic
oedema, urticaria, erythema, collapse
NOS, dyspnoea,
pale mucous membranes)
Lethargy
Neurological disorder (e.g. ataxia,
convulsion,
seizure, muscle tremor)
When injected subcutaneously.
A moderate to severe response can be observed in approximately one third of cats.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.
Good veterinary practice indicates that antiemetics should be used in conjunction
with other veterinary and supportive measures such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting.
The use of this veterinary medicinal product against vomiting due to motion sickness
is not recommended.
Dogs:
Although this veterinary medicinal product has been demonstrated to be effective in
both the treatment and prevention of emesis induced by chemotherapy, it was found
more efficacious if used preventively. Therefore, it is recommended to administer the
antiemetic prior to administration of the chemotherapeutic agent.
Cats:
The efficacy of this veterinary medicinal product in reduction of nausea was
demonstrated in studies using a model (xylazine-induced nausea).

Special precautions for safe use in the target species:
The safety of the veterinary medicinal product has not been established in dogs less
than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or
lactating dogs and cats. Use only according to the benefit-risk assessment by the
responsible veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease. As maropitant is accumulated in the body during a 14-
day treatment period due to metabolic saturation, careful monitoring of liver function
and any adverse events should be implemented during long term treatment.
This veterinary medicinal product should be used with caution in animals suffering from
or with predisposition for cardiac diseases as maropitant has affinity to Ca- and K- ion
channels. Increases of approximately 10% in the QT interval of the ECG were
observed in a study on healthy beagle dogs administered 8 mg/kg orally; however,
such an increase is unlikely to be of clinical significance.
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
veterinary medicinal product at refrigerated temperature may reduce pain at injection.
AN: 04158 & 04159/2024
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
People with known hypersensitivity to maropitant should administer the veterinary
medicinal product with caution.
Wash hands after use. In case of accidental self-injection seek medical advice
immediately and show the package leaflet or the label to the physician. In laboratory
studies, maropitant has been shown to be a potential eye irritant. In the case of
accidental eye exposure, flush the eyes with plenty of water and seek medical
attention.
Special precautions for the protection of the environment:
Not applicable.

The veterinary medicinal product should not be used concomitantly with Ca-channel
antagonists as this veterinary medicinal products has affinity to Ca- channels.
AN: 04158 & 04159/2024
Maropitant is highly bound to plasma proteins and may compete with other highly
bound medicines.

This veterinary medicinal product does not require any special storage conditions.

Not applicable

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.